NOTCH2 and small cell lung carcinoma: OMP-59R5 (tarextumab), which blocks both NOTCH2 and NOTCH3, is effective in treating a variety of tumors397 and has been tested as a treatment for PDAC615, SCLC (NCT01859741), and other solid tumors616 in clinical trials.